Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors.
An increasing body of evidence suggests that a vaccine that elicits anti-HIV-1 cellular immunity could provide the basis for an effective AIDS vaccine. Comparative immunization experiments testing a variety of vaccine approaches have demonstrated that replication-incompetent adenovirus vectors are an effective means for eliciting cytotoxic T-lymphocyte (CTL) immune responses against HIV-1 antigens. These immune responses effectively control viremia in nonhuman primates following challenge with simian AIDS viruses. Such data, coupled with epidemiology studies that identify HIV-1 gag, pol, and nef as the best antigens for broadly directed cellular immune responses, provide guidance for the development of a potential AIDS vaccine.
Shiver
John W
JW
Vaccine Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA. john_shiver@merck.com
Emini
Emilio A
EA
D016915:AIDS Vaccines / Q000235:genetics / Q000627:therapeutic use*; D000256:Adenoviridae / Q000502:physiology*; D000818:Animals; D005822:Genetic Vectors / Q000235:genetics / Q000627:therapeutic use*; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D014779:Virus Replication
D016915:AIDS Vaccines